An experiment in what an agentic-AI research framework can do — published in full so you can check its work, not a tip service to follow. Generic research and education, not advice, not a personal recommendation, not FCA-authorised. Hypothetical book, not real money. Capital at risk.
My Estate by Portfolio Lab
Portfolio Lab — transparent, low-cost portfolios with real out-of-sample performance, net of all costs. View the portfolios →
Portfolio Lab · Research Lab

Research Lab

This is an experiment into what an agentic-AI framework can do — whether disciplined AI agents, held to one rule (a claim only counts if there's evidence it actually predicts returns), can research, decide and honestly track investment ideas. We publish everything in full so you can check the system's work — that openness is the proof, and the whole point. It is deliberately detailed, but it is not a tip service and following it is not the idea: the experiment is the framework and how it performs, not any single stock.

You'll find our analysis of investment signals (which work, which don't, and why), the concepts behind them, deep-dive company research, and a forward-tracked book that keeps an honest score of how the framework's picks do. The book is a hypothetical £20,000 ISA: ideas are held (buy-and-hold), with uninvested cash in short-dated gilts. We size new ideas by conviction (the first few were equal-weight £1,000) and never re-size a position after the fact — so the record shows what we actually did, not a flattering rewrite. Tracked from publication, never a backtest. No real money, no client money, no trades placed.

Please read. This is research and education about a process — not financial advice, not a personal recommendation, and not a tip service. Portfolio Lab is not authorised or regulated by the FCA. Nothing here is tailored to you or suggests that you should buy or sell anything. The book is hypothetical; capital is at risk and past or hypothetical performance is not a reliable indicator of future results. Always do your own research. Read our full disclosures & risk notice →

Signal Research work in progress

The evidence engine behind how we pick — which signals actually predict returns, tested on our own data. Keep-decisions and reject-decisions both matter. See all signal studies →

Concepts

The ideas our framework rests on — how we think, in plain English. See all concepts →

The portfolio we're watching

Headline figures are after Hargreaves Lansdown portfolio costs (dealing, UK stamp, FX, platform); +1.9% before costs — early on, mostly one-off entry costs.

This is the hypothetical portfolio the system runs — the ideas it generates, deployed and tracked honestly with real costs, shown in full for transparency, not positions to follow. A £20,000 ISA: ideas are deployed conviction-weighted (a higher-conviction idea gets more) and then held, while uninvested cash sits in short-dated gilts (~4%). The three lines show pure performance and after Hargreaves Lansdown vs Interactive Brokers costs. Hypothetical — notional money, no trades placed; capital at risk.
Costs so far: IB £28.91 vs HL £236.76 in dealing fees — HL's flat per-trade charges on small holdings are the gap, and the reason platform choice matters.

Live ideas
2
Invested
£20,000
Current value
£20,132
Return (net of costs)
+0.7%
Sharpe
too early to mean much
Max drawdown
-1.7%

Idea tracker & calibration

Closed ideas
5
Hit rate
20%
Avg return
-3.0%
Avg realised R
-0.43R

Calibration — does higher conviction actually win more? Average realised return by conviction, from closed ideas:

ConvictionClosedAvg return
3.5 / 53+3.4%
4 / 52-12.7%

The system's tracked ideas

Instrument ⇅Exchange ⇅ Direction ⇅Conviction ⇅ Published ⇅Since published ⇅ Value ⇅Status ⇅Report
American Express AXP New York Stock Exchange LONG 3.5/5 06 Jun 2026 +9.6% £1284 Live View →
S&P Global SPGI New York Stock Exchange LONG 4/5 06 Jun 2026 -0.9% £1240 Live View →
Intuit INTU NASDAQ LONG 3.5/5 06 Jun 2026 -10.5% £615 Closed View →
RELX REL.L LSE LONG 3.5/5 06 Jun 2026 -12.3% £1020 Closed View →
QinetiQ Group QQ.L LSE LONG 4/5 31 May 2026 -14.6% £854 Closed View →
Keller Group KLR.L LSE LONG 3.5/5 31 May 2026 +33.0% £1330 Closed View →
WEX Inc WEX NYSE LONG 4/5 31 May 2026 -10.7% £893 Closed View →

Research archive

A library of every research report the system rates — including good ideas it didn't put in the live book (shortlisted, on the bench, watchlist, held). The rejects are kept too — see Passed — why the system said no below. Click a column to sort; use the box to filter.

Instrument ⇅Exchange ⇅ Direction ⇅Initial conviction ⇅ Date ⇅Status ⇅
Accenture plc NYSE LONG 2.5/5 2026-06-11 Watchlist
Adobe NASDAQ LONG 3.5/5 2026-06-03 Watchlist
American Express NYSE LONG 3.5/5 2026-06-03 Live
Copart NASDAQ LONG 3/5 2026-06-03 Watchlist
FTI Consulting NYSE LONG 2/5 2026-05-31 Rejected
Games Workshop LSE LONG 3.5/5 2026-06-03 Watchlist
Gartner, Inc. NYSE LONG 2/5 2026-06-11 Watchlist
Intuit NASDAQ LONG 3.5/5 2026-06-03 Closed
JD Sports Fashion LSE LONG 2/5 2026-06-12 Watchlist
Keller Group LSE LONG 3.5/5 2026-05-31 Closed
The Magnum Ice Cream Company LSE LONG 4/5 2026-05-31 Watchlist
QinetiQ Group LSE LONG 4/5 2026-05-31 Closed
RELX LSE LONG 3.5/5 2026-06-03 Closed
Restore plc LSE LONG 2/5 2026-05-31 Watchlist
Roper Technologies NASDAQ LONG 3/5 2026-06-03 Watchlist
Solventum NYSE LONG 3/5 2026-06-03 Watchlist
S&P Global NYSE LONG 4/5 2026-06-03 Live
Veralto NYSE LONG 3.5/5 2026-06-03 Watchlist
WEX Inc NYSE LONG 4/5 2026-05-31 Closed

Passed — why the system said no

Every name the system passes on is kept on the record, price-stamped at the date it passed (2026-06-02), so the system's track record isn't flattered by quietly deleting them. Over time this shows whether the names it declined went on to do well (the filter was too harsh) or badly (it was working). Where the system wrote a full note before declining, the name links to it; the rest carry the one-line reason it passed. Not advice.

Instrument ⇅Price when passed ⇅ Why passed ⇅
Kenvue KVUE $17.35 Dropped at draft stage — now a pending Kimberly-Clark takeover (~$21/sh terms) plus live acetaminophen-autism litigation: a merger-arb with binary legal risk, outside our long-only lens. read the full note →
Moody's MCO $464.20 Wonderful moat, but ~34× earnings — no margin of safety today (watchlist).
Fair Isaac FICO $1284.75 Exceptional pricing power, but ~47× — too expensive to start (watchlist).
MSCI MSCI $643.83 Premium subscription compounder at ~39× — no margin of safety (watchlist).
Visa V $322.77 Superb network, but rich (~29×) — watchlist.
Mastercard MA $495.25 Rich, and the same network thesis as Visa — one is enough.
Chipotle CMG $30.55 Quality compounder at ~27× — no margin of safety (watchlist).
Alphabet GOOGL $376.37 Full valuation (~34×) and little edge we'd add on such a covered mega-cap.
Hilton HLT $332.65 Expensive (~53×) and travel-cyclical.
TransDigm TDG $1238.41 Brilliant model, but ~33× plus a lot of debt — watchlist.
West Pharmaceutical WST $316.30 ~46× even after derating; still working through a destocking headwind.
Texas Instruments TXN $293.20 ~53× on trough earnings during a heavy factory-spending phase.
Old Dominion ODFL $228.53 ~47× plus freight-cycle sensitivity, with no near catalyst.
Chevron CVX $185.83 Largely a bet on the oil price — no durable-quality edge we can underwrite.
KKR KKR $95.01 Market-cycle dependent; our cash-and-quality lens doesn't fit it cleanly.
Capital One COF $184.56 A bank — our quality/cash framework doesn't apply; credit-cycle + integration risk.
CoStar CSGP $33.86 Currently lossmaking on heavy Homes.com investment — the payoff is speculative.
GE Vernova GEV $950.54 ~53× on an electrification theme with thin margins — no margin of safety.
Restaurant Brands QSR $72.86 Mature and levered, with no clear catalyst.
O'Reilly Automotive ORLY $86.09 A relentless compounder, but ~30× earnings — no margin of safety today (watchlist).
UnitedHealth UNH $377.59 Beaten-down quality, but ~20× on still-resetting earnings plus a binary criminal (DOJ) probe and falling Medicare Advantage membership — a falling knife without a floor yet. Revisit when earnings stabilise.
Diploma DPLM.L 6990p Serial-acquirer thesis duplicates Halma — no need for both.
Experian EXPN.L 2644p Premium quality; parked until we add UK fundamentals.
Halma HLMA.L 4794p Premium quality; parked until we add UK fundamentals.